Outset Medical, Inc. (NASDAQ:OM – Get Free Report) CFO Renee Gaeta sold 4,498 shares of the stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $3.67, for a total value of $16,507.66. Following the completion of the transaction, the chief financial officer directly owned 176,342 shares in the company, valued at approximately $647,175.14. This represents a 2.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Outset Medical Trading Down 6.8%
Shares of NASDAQ:OM opened at $3.16 on Wednesday. The stock’s 50-day simple moving average is $3.75 and its two-hundred day simple moving average is $4.09. The stock has a market capitalization of $59.63 million, a price-to-earnings ratio of -0.82 and a beta of 1.93. Outset Medical, Inc. has a 52-week low of $2.84 and a 52-week high of $6.49. The company has a debt-to-equity ratio of 1.19, a quick ratio of 3.85 and a current ratio of 4.86.
Outset Medical (NASDAQ:OM – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.01. Outset Medical had a negative net margin of 58.33% and a negative return on equity of 66.98%. The firm had revenue of $33.60 million during the quarter, compared to analyst estimates of $31.40 million. Analysts expect that Outset Medical, Inc. will post -3.51 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of brokerages have commented on OM. Weiss Ratings cut shares of Outset Medical from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 21st. Wall Street Zen upgraded shares of Outset Medical from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $10.00.
Check Out Our Latest Report on Outset Medical
Institutional Trading of Outset Medical
Hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC lifted its position in shares of Outset Medical by 391.3% during the 1st quarter. Renaissance Technologies LLC now owns 222,075 shares of the company’s stock valued at $853,000 after buying an additional 176,870 shares in the last quarter. Marshall Wace LLP grew its stake in shares of Outset Medical by 128.0% during the 3rd quarter. Marshall Wace LLP now owns 483,380 shares of the company’s stock valued at $1,450,000 after acquiring an additional 271,387 shares during the period. Empowered Funds LLC purchased a new stake in Outset Medical in the 3rd quarter worth approximately $74,000. Squarepoint Ops LLC purchased a new stake in Outset Medical in the 2nd quarter worth approximately $98,000. Finally, Bank of New York Mellon Corp purchased a new stake in Outset Medical in the 2nd quarter worth approximately $121,000.
About Outset Medical
Outset Medical is a medical technology company that develops and sells products for hemodialysis, a treatment that filters waste and excess fluid from the blood. Its main product is the Tablo Hemodialysis System, an integrated dialysis platform designed for use in hospitals, clinics and home settings. Tablo combines dialysis equipment with water purification and a touchscreen interface, aiming to simplify treatment setup and operation. The system also supports access to treatment data through connected software tools.
Further Reading
- Five stocks we like better than Outset Medical
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Outset Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outset Medical and related companies with MarketBeat.com's FREE daily email newsletter.
